Skip to content

Denali Therapeutics

US · DNLI #2454 by market cap Listed 2017
19.16 -0.12 -0.62%
Live - 5344 symbols - heartbeat 400s ago · 2026-10-08 07:00
Pre-market 19.06 -0.52%
After-hours 19.16 0.00%
Overnight 19.16 0.00%
Market cap
3.06B
P/B
3.67
EPS
-2.97
Reader sentiment Are you bullish or bearish on DNLI?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31
    Market Newswire · 2026/7/15
  • B. Riley Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/8/25
  • Rating change
    BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/5/11
  • Rating change
    Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36
    Market Newswire · 2026/7/23
  • Rating change
    Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/5/26
  • Rating change
    William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating
    Market Newswire · 2026/5/9
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CG Oncology, Inc. (CGON) and Denali Therapeutics (DNLI)
    TipRanks · 2026/5/9
  • Rating change
    Baird Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
    Market Newswire · 2026/4/7
  • Rating change
    J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $29
    Market Newswire · 2026/7/13
  • Rating change
    Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $23
    Market Newswire · 2026/5/8
  • UBS Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/6/16
  • Rating change
    A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41
    Market Newswire · 2026/8/7
  • Rating change
    Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $40
    Market Newswire · 2026/5/14
  • Rating change
    H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/7/13
  • Rating change
    Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/7/16
  • Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/7/13
  • A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42
    Market Newswire · 2026/8/8
  • J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/8/11
  • Rating change
    Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/5/11
  • Rating change
    TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
    Market Newswire · 2026/5/9

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:00:03 · For reference only, not investment advice and not tailored to your situation.